NQMC Update Service: September 28, 2015 ► American Society of Hematology

NQMC Update Service: September 28, 2015

American Society of Hematology

• Myelodysplastic syndromes (MDS): percentage of higher-risk MDS patients receiving azacitidine or decitabine.

• Myelodysplastic syndromes (MDS): percentage of MDS patients presenting with anemia who had a serum erythropoietin level less than or equal to 500 mU/ml prior to receiving erythropoietin/darbepoetin therapy.

• Myelodysplastic syndromes (MDS): percentage of MDS patients presenting with anemia who had evidence of adequate iron stores within 60 days prior to receiving erythropoietin/darbepoetin therapy.

• Myelodysplastic syndromes (MDS): percentage of MDS patients who are candidates for allogeneic stem cell transplant receiving irradiated transfusion products.

• Myelodysplastic syndromes (MDS): percentage of MDS patients who had an established pathologic classification/risk prognostication system to help plan therapeutic options.

• Myelodysplastic syndromes (MDS): percentage of MDS patients whose baseline diagnostic evaluation includes cytogenetic testing on bone marrow by standard karyotyping methods.

• Myelodysplastic syndromes (MDS): percentage of patients with a diagnosis of MDS whose eligibility for a clinical trial was checked at least once a year.